

Depot medroxyprogesterone acetate (DMPA) injections: an intermediate option

Depot medroxyprogesterone acetate injections are a form of hormonal contraception administered every 12 weeks for optimal effect. Despite being associated with variable changes in bleeding patterns and a delayed return to fertility when stopped, it is a preferred method of contraception for many people as it does not rely on daily adherence or require an insertion procedure.

KEY PRACTICE POINTS:

- DMPA injections are a highly effective form of contraception; the estimated rate of pregnancy during the first year of use is 2 per 1000 if administered every 12 weeks
- DMPA injections are a suitable option in many cases when oestrogen-containing contraceptives are contraindicated
- The decision to initiate use should involve a comprehensive discussion regarding the potential risks and adverse effects; in particular, the patient should be aware that irregular bleeding patterns are common during the first year of use and that return to fertility can be delayed after stopping injections
- Approximately half of those receiving DMPA injections report amenorrhoea after 12 months of use, which may be beneficial in those who have experienced menorrhagia or dysmenorrhoea during their menstrual cycle
- Although evidence of adverse clinical outcomes is lacking, DMPA injections are associated with a reduction in bone mineral density, therefore alternative methods of contraception should be considered first in those aged under 18 years or of any age with risk factors for osteoporosis
- The risks and benefits should be re-evaluated at least once every two years in every person using this form of contraception

Depot medroxyprogesterone acetate (DMPA) injections are an effective form of hormonal contraception

DMPA (Depo-Provera) is a fully subsidised form of progestogen-only contraception administered via intramuscular injection.¹ Its primary effect is to reduce the chance of ovulation by limiting follicle stimulating hormone and luteinizing hormone secretion.¹ In addition, DMPA injections can alter cervical mucus to prevent sperm penetration, as well as thin the endometrial lining to make it unsuitable for implantation.¹

DMPA injections may be preferred by people who:^{1,2}

- Have difficulty adhering to daily oral contraceptive regimens, e.g. working irregular shifts, forgetful with daily medicine use
- Prefer a contraceptive with prolonged action but have concerns over the more invasive insertion procedures associated with levonorgestrel implants and intrauterine devices
- Have a contraindication or caution for oestrogen use, e.g. migraine with aura

DMPA injections may also be a useful treatment for heavy menstrual bleeding or dysmenorrhoea, although its effects on bleeding are unpredictable (see “Altered bleeding patterns are common”).

Highly effective contraception when administered on time

When administered at the recommended dose (150 mg) and frequency (every 12 weeks), DMPA has a failure rate of approximately 0.2% in the first year of use, i.e. two pregnancies per 1,000 people treated.² Although not encouraged, injections can be given up to 14 weeks after the previous dose without compromising the contraceptive effect if necessary, e.g. if the person is travelling and is unable to attend their 12-week appointment. Clinical studies used to derive “perfect use” failure rates included patients receiving injections every 13 weeks ± seven days.³

With typical use of DMPA, which includes inconsistent, late or incorrect use, the failure rate has been estimated at 6%, which is higher than for long-acting reversible contraceptives (LARCs), e.g. levonorgestrel implants.^{1,2} For this reason, along with the fact that effectiveness is user-dependent, organisations such as the Royal Australian and New Zealand College of Obstetricians and Gynaecologists no longer consider DMPA injections to be a form of LARC.⁴

Injections are generally well-tolerated


DMPA injections are usually well-tolerated, but adverse effects can include acne, nausea, headaches and hot flushes, the occurrence of which will typically decrease over time.⁵ Menstrual irregularities and weight gain can also occur, which may be unacceptable for some people (see “Balancing the benefits and risks of DMPA injections”).¹

Administering DMPA injections

- The upper outer quadrant of the buttock (i.e. dorsogluteal site) is the preferred IM injection site; the ventrogluteal site is an alternative, to reduce sciatic nerve injury. If excessive adipose tissue is present the deltoid muscle site is another alternative that can be used.¹
- The first injection should be given within the first five days of starting of a menstrual cycle or within the first five days after giving birth; however, the risk of heavy or prolonged bleeding is increased when injections are administered shortly after giving birth.^{1,5}
 - If breastfeeding, it is generally recommended to delay the first injection until six weeks after giving birth (see: “DMPA injections can be used while breastfeeding”).^{1,5}
- No additional contraception is needed when injections are started within the first five days of the menstrual cycle; if initiated later in the menstrual cycle, additional contraception should be used for seven days following the first injection with a follow up pregnancy test recommended four weeks later¹
- Although repeat injections should be given every 12 weeks, they can be administered between 10 and 14 weeks if necessary (Table 1).^{1,2}

Table 1. Guidance for repeat DMPA injections administered outside the recommended 12 week interval^{1,2}

Time since last injection	Recommendation
10–12 weeks	Consider administering injection early if bleeding occurs; exclude other causes if bleeding is very heavy
12–14 weeks	Administer injection; no additional contraception is required
>14 weeks	Perform a pregnancy test and consider emergency contraception; administer injection if pregnancy is excluded and recommend additional contraception for seven days

 For further information on performing intramuscular injections, see: www.bpac.org.nz/BPJ/2015/December/correspondence.aspx#3

Symptoms to monitor. Patients should be advised to report any new-onset chest pain, deep unilateral leg pain or shortness of breath, and investigated for the possibility of a thromboembolic event (see “Cardiovascular risk factors may be a reason not to use DMPA injections”).⁵ Mood changes are also sometimes reported.⁶ It is recommended that patients with a history of clinical depression are closely monitored during treatment, and the injections stopped if a significant relapse occurs.⁵

Suitable if given concurrently with hepatic enzyme-inducing medicines. A notable advantage of DMPA over other forms of hormonal contraception is that its effectiveness is not influenced by the use of hepatic enzyme-inducing medicines, e.g. antiepileptic medicines, so they can be used at the same time.⁷

When should DMPA injections be avoided?

DMPA injections are contraindicated in people with:^{*2,8}

- Current breast cancer or a history of breast cancer; although it may be considered if other forms of contraception are inappropriate and the cancer has been in remission for at least five years
- Undiagnosed vaginal or urinary tract bleeding
- Thrombophlebitis or thromboembolic disorders, or in those with a history of these conditions
- Poorly controlled hypertension; systolic blood pressure \geq 160 mmHg or diastolic \geq 100 mmHg
- Multiple cardiovascular risk factors
- Severe hepatic dysfunction, e.g. people with decompensated cirrhosis or malignant hepatic tumours

* For a full list of contraindications and cautions, e.g. systemic lupus erythematosus, refer to the NZF at: https://nzf.org.nz/nzf_10051 and the United Kingdom Medical Eligibility Criteria: www.fsrh.org/standards-and-guidance/external/ukmec-2016-digital-version/

Balancing the benefits and risks of DMPA injections

Before beginning treatment, it is important to discuss the potential benefits and risks of DMPA injections and to emphasise that its effectiveness is dependent on adherence.

Altered bleeding patterns are common

DMPA injections are likely to cause changes in bleeding pattern such as amenorrhoea, irregular bleeding or spotting, or prolonged bleeding.² As the duration of use increases, amenorrhoea becomes more likely (Table 2).¹ Altered bleeding patterns are the most frequent reason for stopping DMPA use in the first year; if information is provided about this and people are reassured that irregular bleeding patterns are normal, and

are likely to settle, it may help with longer term adherence. If bleeding is persistent or problematic, after excluding other causes (e.g. cervical pathology), it can be managed using pharmacological intervention (see “Managing persistent or problematic bleeding”).⁸⁻¹⁰ In women with heavy menstrual bleeding that persists despite pharmacological intervention, an alternative method of contraception may be more suitable, e.g. a levonorgestrel IUD.

Changes in bleeding may be beneficial for some, but are unpredictable

In some people, reduced bleeding or amenorrhoea may be desirable, such as those with menorrhagia or dysmenorrhoea, or those that experience anaemia as a result of their heavy bleeding.^{1,2} However, as the bleeding patterns associated with DMPA are unpredictable, this may be an unreliable management strategy. In people with endometriosis, DMPA injections (using a different dosing regimen*) can be useful for reducing bleeding symptoms and pelvic pain.^{2,8}

* Injections are administered at a dose of 50 mg weekly or 100 mg every two weeks for at least six months.⁸


 For further information on the pharmacological management of endometriosis, see: www.bpac.org.nz/bpj/2013/april/endometriosis.aspx

Table 2. Prevalence of altered bleeding patterns in people administered DMPA injections

Altered bleeding pattern	After three months	After 12 months
Amenorrhoea ¹	10%	47%
Irregular bleeding ^{9,11}	15%	9%
Prolonged bleeding ¹²	33%	12%

There is often a delay in the return to fertility with DMPA injections

A significant factor influencing the decision to use DMPA injections is its association with a delay in the return to fertility once treatment is stopped. This delay is variable, with one follow-up study reporting an average of six months (range two to eleven months) for return of ovulation.^{1,13} There is no evidence that DMPA injections cause a permanent loss of fertility. Following the final injection, it is estimated that 65% of those who wish to become pregnant do so within 12 months, 83% do so within 15 months and 93% do so within 18 months (median time ten months).⁵ As such, those wanting to become pregnant in the near future or shortly after stopping contraceptives should consider an alternative

method of contraception until they are ready to conceive. If DMPA injections are stopped, another contraceptive should be initiated at the time the next injection would have been due.¹

DMPA injections can be used while breastfeeding

DMPA injections are considered safe to use while breastfeeding.^{1, 8, 14} The manufacturer recommends delaying administration until six weeks post-partum if breastfeeding, due to theoretical concerns over an infant's ability to metabolise DMPA.⁵ However, there is no evidence of adverse effects on infant growth, health or development or on breastfeeding performance, therefore the UKMEC considers the benefit of

use of DMPA in the first six weeks post-partum to outweigh the risks.¹⁴ The UK FSRH guidelines advocate the use of DMPA post-partum but recommend to ideally delay administration until day 21 if breastfeeding.¹

DMPA injections are associated with a small amount of weight gain

Current evidence suggests that DMPA injections are the only form of contraception associated with weight gain.¹⁵ In clinical studies, an average increase in weight of one to two kilograms over one year of use has been reported.^{2, 15} Weight gain appears to increase with longer durations of treatment and is most strongly associated with use in people aged under 18 years with an initial body mass index ≥ 30 kg/m².¹⁵ Switching to an alternative method of contraception may be advised in those who gain more than 5% of their initial body weight within six months as continued weight gain is likely.¹⁵

Managing persistent or problematic bleeding while using DMPA

First-line options (recommended in clinical guidelines)

- A combined oral contraceptive for up to three months (with or without placebo pills), e.g. 30 micrograms ethinylestradiol with levonorgestrel or norethisterone;¹⁰ one month is usually sufficient to manage abnormal bleeding
- Oral mefenamic acid 500 mg (partly subsidised), two to three times daily, for up to five days; OR oral tranexamic acid 1 g (fully subsidised), three to four times daily, for up to four days, can be used to reduce an episode of heavy bleeding¹⁰

Second-line options (low-level, anecdotal or conflicting evidence)

- Oral medroxyprogesterone acetate* 10 mg (fully subsidised), once daily, for 21 days^{8, 9}
- Oral norethisterone 5 mg (fully subsidised), two to three times daily, for 21 days⁹

* Family Planning New Zealand recommends oral medroxyprogesterone acetate as the preferred second-line option. This is because there is concern that at high doses norethisterone is converted into oestrogenic compounds, which is not suitable for women who have a contraindication to oestrogen treatment.

Other potential health concerns are not well defined

Be aware of potential changes in bone mineral density


DMPA injections are associated with a small reduction in bone mineral density due to its hypo-oestrogenic effect.^{1, 2} This form of contraception is therefore not a first-line choice in people aged under 18 years as there are concerns that it may influence peak bone mineral density.¹ It is recommended that the benefits and risks of treatment should be reassessed every two years, and if risk factors for osteoporosis are identified, e.g. rheumatoid arthritis, inflammatory bowel disease, age over 50 years or perimenopausal, an alternative method of contraception should be recommended.^{1, 2}

Further investigation is required to understand the consequences of these changes

It is not known whether the changes in bone mineral density with DMPA use results in an increased fracture risk or whether longer durations of treatment cause greater losses.¹ Some studies suggest that the rate of bone mineral density loss is more significant during the first two years of treatment and slows with continued use, however, this finding has not been consistently replicated. In general, any losses are reversed once treatment is stopped.¹

The association with cancer risk requires further investigation

Breast cancer. Evidence on the risk of breast cancer in people who have taken DMPA injections is limited.¹ Studies have indicated there may be a weak association – similar to findings with combined oral contraceptives – but absolute increases in risk are generally low and appear to diminish once treatment



is discontinued, e.g. there is no increased risk more than five years after treatment ceases.¹

Cervical cancer. Studies have found a slightly increased risk of cervical cancer in people using DMPA injections for five years or more, however, it is not clear if the association is causal or whether confounding factors are involved.¹ As with breast cancer, the risk reduces after stopping treatment.

Other conditions. DMPA injections are not associated with an increased risk of endometrial or ovarian cancers and evidence suggests they may actually have a protective effect.^{1, 6, 16} In addition, studies indicate a potentially reduced risk of colon cancer, acute episodes of pelvic inflammatory disease and ectopic pregnancy when using this form of contraception, however, further investigation is required to confirm these benefits.

Cardiovascular risk factors may be a reason not to use DMPA injections

The effect of taking DMPA injections on cardiovascular disease risk remains under scrutiny. A small increase in the

risk of venous thromboembolism (VTE) has been noted in clinical trials of progestogen-only contraceptives, however, a causal relationship has not been confirmed specifically for DMPA injections.¹ In addition, it should be considered that the risk of VTE is considerably lower than that associated with pregnancy or use of combined oral contraceptives. There is also insufficient evidence to conclude whether myocardial infarction and stroke are associated with DMPA. In general, clinical decisions should be made based on the severity and number of risk factors, in addition to the likelihood of follow-up. For example, DMPA injections should usually not be used if the person has multiple risk factors for arterial cardiovascular disease, e.g. hypertension and diabetes.²

Acknowledgement: Thank you to **Dr Beth Messenger**, National Medical Advisor, Family Planning New Zealand for expert review of this article

N.B. Expert reviewers do not write the articles and are not responsible for the final content.

.....

References:

1. Faculty of Sexual and Reproductive Healthcare. FSRH clinical guidance: progestogen-only injectable contraception. 2014. Available from: www.fsrh.org/standards-and-guidance/documents/cec-ceu-guidance-injectables-dec-2014/ (Accessed Feb, 2019).
2. World Health Organization (WHO), Research (WHO/RHR) and Johns Hopkins Bloomberg School of Public Health/Center, for Communication Programs (CCP), Knowledge for Health Project. Family planning. A global handbook for providers (2018 update). 2018. Available from: www.who.int/reproductivehealth/publications/fp-global-handbook/en/ (Accessed Feb, 2019).
3. Trussell J. Contraceptive failure in the United States. *Contraception* 2011;83:397–404. doi:10.1016/j.contraception.2011.01.021
4. Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG). Long acting reversible contraception. Victoria, Australia: RANZCOG 2017. Available from: www.ranzcog.edu.au/college-statements-guidelines.html (Accessed Feb, 2019).
5. Pfizer New Zealand. Data sheet. Depo-Provera. 2014. Available from: <http://www.medsafe.govt.nz/profs/datasheet/d/Depoproverainj.pdf> (Accessed Feb, 2019).
6. Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG). Depot medroxyprogesterone acetate. Victoria, Australia: RANZCOG 2015. Available from: <https://www.ranzcog.edu.au/college-statements-guidelines.html> (Accessed Feb, 2019).
7. Faculty of Sexual and Reproductive Healthcare. CEU clinical guidance: drug interactions with hormonal contraception. 2018. Available from: www.fsrh.org/standards-and-guidance/documents/ceu-clinical-guidance-drug-interactions-with-hormonal/ (Accessed Feb, 2019).
8. New Zealand Formulary (NZF). NZF v80. 2019. Available from: www.nzf.org.nz (Accessed Feb, 2019)
9. Guidance for management of troublesome vaginal bleeding with progestogen-only long-acting reversible contraception (LARC). Family Planning Alliance Australia. 2019. Available from: <https://www.fpnsw.org.au/health-information/contraception/guidance-management-troublesome-vaginal-bleeding-progestogen-only> (Accessed Feb, 2019).
10. Faculty of Sexual and Reproductive Healthcare. FSRH clinical guidance: problematic bleeding with hormonal contraception. 2015. Available from: www.fsrh.org/standards-and-guidance/documents/ceuguidanceproblematicbleedinghormonalcontraception/ (Accessed Feb, 2019).
11. Said S, Omar K, Koetsawang S, et al. A multicentered phase III comparative clinical trial of depot-medroxyprogesterone acetate given three-monthly at doses of 100 mg or 150 mg: II. The comparison of bleeding patterns. *World Health Organization. Task Force on Long-Acting Systemic Agents for Fertility Regulation Special Programme of Research, Development and Research Training in Human Reproduction. Contraception* 1987;35:591–610.
12. Depo-Provera 150mg/ml Injection. SmPC. Electronic Medicines Compendium (eMC). 2018. Available from: <https://www.medicines.org.uk/emc/product/6721/smpc> (Accessed Feb, 2019).
13. Jain J, Dutton C, Nicosia A, et al. Pharmacokinetics, ovulation suppression and return to ovulation following a lower dose subcutaneous formulation of Depo-Provera. *Contraception* 2004;70:11–8. doi:10.1016/j.contraception.2004.01.011
14. Faculty of Sexual and Reproductive Healthcare. UK Medical Eligibility Criteria for contraceptive use (UKMEC). 2016. Available from: www.fsrh.org/standards-and-guidance/uk-medical-eligibility-criteria-for-contraceptive-use-ukmec/ (Accessed Feb, 2019).
15. Faculty of Sexual and Reproductive Healthcare. CEU statement: weight and contraception. 2017. Available from: www.fsrh.org/standards-and-guidance/documents/ceu-statement-weight-and-contraception-april-2017/ (Accessed Feb, 2019).
16. Lieberman A, Curtis L. In defense of progesterone: a review of the literature. *Altern Ther Health Med* 2017;23:24–30.



This article is available online at:
www.bpac.org.nz/2019/contraception/depot.aspx